ABL Bio - medicine for A Better Life

Dr. Lee founded ABL Bio in February 2016 with the vision to build a company that offers patients a better life based on innovative science. Recognizing that bispecific antibodies are the key to next-generation therapeutics, Dr. Lee has focused on diversifying ABL’s portfolio of bispecific antibody-based treatments for cancer and neurodegeneration. Under his leadership, ABL has advanced four bispecific antibodies into clinical trials, demonstrating unprecedented speed and commitment among South Korean biotechnology companies.

Prior to ABL, Dr. Lee co-founded PharmAbcine where he oversaw all research and development for antibody therapeutic projects. Before that, he was responsible for drug discovery and preclinical development as the Head of the Bio Division at Hanwha Chemical.

Dr. Lee also brings years of experience from global biopharmaceutical companies, including Chiron(Novartis), AstraZeneca, Genentech and Exelixis, where he gained cross functional knowledge in drug discovery, preclinical and clinical development of therapeutic antibodies.

Dr. Lee received his Ph.D. in Molecular, Cellular and Developmental Biology at The Ohio State University and obtained his postdoctoral fellowship at the Harvard Medical School and UCSF. He earned his M.S. in Developmental Biology and B.S. in Biology Education from Seoul National University.

Jerry is a founding member of ABL Bio, where he is responsible for all managerial and financial functions of the company, including financial strategy, capital investment, accounting, investor and public relations and risk-managing. He also oversees all global and domestic partnership activities.

Jerry previously served as Vice President of the Bio Division at Hanwha Chemical, where he supervised the Division’s corporate strategy. Before joining Hanwha, Jerry was a Director at Deloitte Consulting where he led life-science and healthcare practices. He began his professional career as an associate consultant at Oliver Wyman.

Jerry holds an M.B.A. and M.H.S.A. from the University of Michigan and received his B.A. in Business Administration from Korea University.

Dr. You heads all research and development strategies at ABL Bio. He leads efforts to strengthen the company’s portfolio of bispecific antibody cancer immunotherapies and neurodegenerative disease therapies.

Dr. You has extensive experience in leading antibody projects from discovery to nonclinical stages. Throughout his career, he has achieved more than 30 scientific publications and multiple worldwide patents. Before ABL, Dr. You was a Principal Scientist at Hanwha Chemical, where he managed the development of novel anti-cancer therapeutic antibodies. Prior to Hanwha, he worked as a researcher at the Sanford-Burnham Medical Research Institute. In his earlier career, he developed novel therapeutics at the Mogam Biotechnology Research Institute and Iljin Materials.

Dr. You is a graduate of Yonsei University with a Ph.D., M.S. and B.S. in Biochemistry. He completed his postdoctoral fellowship at the University of California, San Francisco.

Dr. Kim leads clinical development at ABL Bio. She is responsible for setting clinical development strategies based on the asset profiles and unmet medical needs. She manages the clinical projects and team, while collaborating with various partners to accelerate clinical development of ABL Bio’s portfolio in the relevant disease areas.

Dr. Kim has broad experience in drug development, especially in the oncology therapeutic area. Before joining ABL Bio, she worked at the eminent multinational pharmaceutical companies since 2008. Dr. Kim led the oncology clinical development team for Bristol-Myers-Squibb (BMS) Japan and served as an oncology medical specialist for Asia pacific countries. Prior to BMS, she worked at Novartis Oncology, leading global and local development and medical affairs for Korea.

Dr. Kim is a graduate of Seoul National University with a Ph.D., M.S., and M.D. in College of Medicine. She was also educated at University of Basel’s European Center for Pharmaceutical Medicine in Switzerland.

Dr. Jung is responsible for discovery at ABL Bio. He has a demonstrated background in oncology and immunology with experience in the execution of preclinical studies in a regulatory industry setting.

Prior to this role, Dr. Jung was a Principal Scientist at Agensys, Inc., where he managed the development of pre-clinical in vivo tumor models, evaluated investigational immuno-oncology therapeutics and antibody drug conjugates by conducting efficacy, PK, PD and MOA studies. He was previously the R&D director at HepaHope where he led the preclinical study planning and execution of IND-enabling in vitro and in vivo studies. Earlier in his career, Dr. Jung was involved in antibody discovery and tumor immunology at Biogen Idec.

He gained his Ph.D. in Immunology at the Ohio State University and conducted his postdoctoral research at Stanford University and the Ochsner Clinic Foundation. He holds a M.S. in Microbiology and B.S. in Biology at Konkuk University.

Since joining ABL in 2019, Mr. Kim has been responsible for all aspects of the human resources agenda, including talent acquisition, compensation, benefits, employee relations and inclusive working environment.

Mr. Kim brings nearly three decades of experience from Hewlett-Packard Enterprise Korea. He held various leadership roles covering a broad range of areas, including channel service management, account management, customer experience, business strategy planning and field development. He also supervised learning and development programs to enhance organizational effectiveness.

He obtained his M.B.A. from Sogang University and bachelor’s degrees in Aeronautical Science & Flight Operation and Electric Engineering from the Korea Aerospace University

Dr. Sung-Ju Moon is Executive Vice President and Chief ADC Development Officer at ABL Bio, where he oversees all antibody–drug conjugate (ADC) research, development, and strategic initiatives. With over two decades of experience in ADC innovation, Dr. Moon has played a pivotal role in advancing multiple first-in-class ADC programs and continues to lead ABL Bio’s efforts to develop next-generation targeted cancer therapeutics. Before joining ABL Bio in 2025, Dr. Moon made significant contributions to the field at Immunomedics (now part of Gilead Sciences) as the first author and lead inventor of Trodelvy™, and at Astellas Pharma with Padcev™. He also led ADC and ISAC technology development at Ambrx Biopharma (Johnson & Johnson) and IntoCell Inc., securing multiple patents and contributing to their successful IPOs and acquisition by global pharmaceutical company. Dr. Moon earned his B.S. in Chemistry and M.S./Ph.D. in Organic Chemistry from Seoul National University. He then completed postdoctoral fellowships in Medicinal Chemistry at the University of Texas at Austin and the University of Virginia, where he co-founded and established a new research laboratory. Dr. Moon, a registered U.S. patent agent (USPTO LIC#73191) and recipient of the 2014 Thomas Edison Patent Award, continues to bridge chemistry and biology to drive innovation in next-generation ADC therapeutics.

Dr. Kwon has over 20 years of experience in the pharmaceutical and biotech industry, with extensive target validation to preclinical development experience. At ABL Bio, he leads the neuroscience and non-clinical development teams. Before joining ABL Bio, Dr. Kwon served as Director at Sanofi, where he spearheaded the development of novel vaccines and therapeutic molecules for autoimmune disease and allergy. His earlier roles include Senior Scientist at Abbvie/Abbott and Staff Scientist at Facet Biotech/PDL Biopharma in the field of immune-oncology, cancer and immunology, where he contributed to the advancement of cutting-edge therapeutics. Dr. Kwon earned his Ph.D. in Experimental Medicine and B.S. in Biochemistry from McGill University.